Imaging AI in Maryland

BrainScope is a commercial-stage medical neurotechnology company specializing in AI-powered EEG-based diagnostic solutions for brain health. Founded in 2006 and based in Rockville, Maryland, BrainScope has developed a proprietary platform that applies machine learning and computational neuroscience to transform brain electrical activity (EEG) into objective clinical biomarkers. The company created the first FDA-cleared AI/Machine Learning medical device in neurology and holds a portfolio of 83 issued patents. BrainScope's primary offering is a hand-held, point-of-care device for assessing mild traumatic brain injuries (mTBI), structural brain bleeds, and concussions in under 20 minutes. The technology has demonstrated ~50% reduction in unnecessary head CT scans and substantial reductions in emergency department patient length of stay. Beyond head injury assessment, BrainScope is developing novel biomarkers for stroke detection, early Alzheimer's detection (with dementia risk prediction up to 7 years before initial diagnosis), and other CNS indications. The company serves acute care settings, hospitals, emergency departments, and pharmaceutical/drug development partners.

PediaMetrix is a healthcare technology company specializing in AI and computer vision solutions for pediatric care. The company's flagship product, SoftSpot™, is the first and only FDA-cleared mobile application for point-of-care measurements of infant head deformity conditions, including positional plagiocephaly and other cranial abnormalities. SoftSpot enables both pediatric providers and parents to perform quantitative, repeatable head shape assessments using smartphone-based computer vision technology, supporting early detection and monitoring in clinical and home environments. The platform is designed for telemedicine and in-office use, with results interpreted by qualified healthcare professionals. PediaMetrix also offers Tummy Time Tools to support infant developmental activities. The company's mission is to make advanced measurement technology accessible to improve patient outcomes and reduce costs in pediatric healthcare delivery while maintaining robust data security through encryption systems.

Personal Genome Diagnostics (PGDx) is a precision oncology diagnostics company specializing in comprehensive genomic profiling (CGP) solutions for solid tumors. The company offers kitted genomic testing platforms designed to democratize access to cancer genomics in distributed laboratory settings worldwide. PGDx manufactures FDA-cleared and CE-IVD marked tissue and plasma-based assays that enable rapid, actionable genomic insights without requiring centralized laboratory infrastructure. The PGDx elio tissue complete test profiles 500+ solid tumor-related genes with somatic mutation identification including SNVs, indels, tumor mutational burden (TMB), microsatellite instability (MSI), and select amplifications and translocations. The PGDx elio plasma complete assay is a liquid biopsy solution analyzing circulating tumor DNA for biomarker discovery across pan-solid tumors, eliminating the need for invasive tissue sampling. Both platforms integrate proprietary bioinformatics for fully automated data analysis and clinical reporting. The company supports early-stage and late-stage biopharma services including biomarker discovery, companion diagnostic (CDx) development, and translational research. PGDx is now part of the LabCorp network, enhancing service delivery and clinical laboratory partnerships globally. Products are backed by turn-key bioinformatics enabling in-house testing and local control of genomic data.

Clear Guide Medical develops augmented reality (AR) and artificial intelligence (AI) guided procedural imaging software compatible with MRI, CT, and ultrasound systems. The company's core platform, SCENERGY, enables real-time image guidance for minimally invasive interventional procedures including biopsies, ablations, and other needle-based therapies. SCENERGY enhances procedural accuracy, reduces intermediate imaging steps, and improves workflow efficiency while decreasing complications and adjacent tissue damage. The platform includes SCENERGY-TP (tissue penetration variant), SCENERGY Navigation for enhanced spatial mapping, SCENERGY Fusion for multi-modality registration, and proprietary tracking solutions (VisiMARKERS and TipTAGs) that enhance needle and instrument visualization. The technology has been validated in clinical settings at Johns Hopkins Hospital and Mount Sinai Beth Israel, with peer-reviewed publications demonstrating improved confidence, speed, and accuracy for both novice and experienced operators. Products are FDA-cleared and designed for integration into existing hospital imaging workflows. Clear Guide serves hospitals, clinics, and academic medical centers, offering research partnerships and institutional licensing. The company provides technical support, user manuals, and training resources.